Gilead in Singapore - A Diverse and Vibrant Team

Gilead Sciences, with support from the community-based organizations from Singapore and Hong Kong, conducted a qualitative survey to understand the perceptions of people living with HIV (PLWH) on health management and quality of life. The findings highlight areas that can be strengthened, such as improvement on patient-HCP communication, patient empowerment throughout their care journey, increased awareness on chronic diseases such as renal conditions and mental health. Gilead will continue to work with local partners to enhance quality of life for PLWH.

Click here for the detailed findings.

Since 2022, Gilead has supported the government’s public health goals to eliminate viral hepatitis by partnering with HCSA Community Services to test and treat hepatitis C (HCV) among high-risk populations such as former drug offenders, newly released prisoners, and those in recovery from addiction. The initiative has further expanded in 2023 to cover six more halfway houses to ensure a greater reach.

To mark Breast Cancer Awareness Month in October, Gilead employees and their families joined the Breast Cancer Foundation’s annual Pink Ribbon Walk to celebrate solidarity, hope, and courage for those impacted by the disease. It is a meaningful initiative to raise awareness of breast cancer and to pay tribute to breast cancer survivors by recognizing their resilience and triumph over adversity.

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing. At Gilead and Kite Oncology, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy in Singapore to as many eligible patients as possible who may benefit, because we believe cell therapy has the ability to change the way cancer is treated.

In a first of its kind public-private-academic initiative, Gilead is collaborating with the Partnership for Health Advancement in Vietnam, Brigham and Women’s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center to address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries where hepatitis B and C are endemic, and where governments are committed to reaching the WHO goal to eliminate viral hepatitis by 2030. The partnership includes working with provincial and district hospitals in Hanoi and Thai Bin, Vietnam and Manila and Tarlac in the Philippines.